Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA focuses on neurodegenerative diseases and utilizes proprietary technology to develop innovative therapies targeting protein misfolding, notably through its diverse pipeline, which includes advanced candidates like ACI-7104.056. The upcoming readout from this candidate is expected to provide critical insights, particularly given its previous successes in raising antibodies to pathogenic variants of aSyn by 20 times, which could enhance its therapeutic potential. Additionally, the strategic use of mAbs with titration dosing schemes positions the company favorably in the evolving treatment landscape for Alzheimer's disease, indicating a promising outlook for its therapeutic innovations.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, indicating significant financial challenges for the clinical-stage biopharmaceutical company. The company operates in a highly competitive field characterized by unpredictable clinical outcomes, regulatory uncertainties, and evolving commercial dynamics that can impact market viability. These factors contribute to an overall negative outlook, as the risks associated with its clinical pipeline may limit investor confidence and hinder financial stability.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.